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Simple Summary: Gastric cancer is one of the most common cancers worldwide, showing high
mortality rates. A small portion of gastric cancer patients, known as early onset gastric cancer (EOGC)
patients, develop the disease before age 50, and their characteristics are poorly described. Thus,
our main objective was to describe the clinical, molecular, and genetic characteristics of EOGC in a
large multicenter cohort of patients. We were able to identify that most EOGC cases have similar
characteristics: diagnosed at advanced stage, diffuse type, and infrequent DNA mismatch repair
somatic deficiency. Although familial aggregation of gastric cancer was uncommon, a germline
genetic mutation was identified in 25% of the patients tested. Our results show that EOGC has a
marked genetic heterogeneity. Thus, it is essential to consider familial history of tumors, not only
GC, in order to select adequate patients to perform a suitable genetic counseling and enhance the
emerging use of multigene panels.
Abstract: Gastric adenocarcinoma (GC) is a common tumor with high morbidity and mortality.
Only 7% of patients with GC are diagnosed before age 50 (early onset gastric cancer (EOGC)), and
their characteristics have been poorly described. We aimed to describe clinical, molecular, and
genetic characteristics of EOGC. A total of 309 patients with EOGC were retrospectively studied in
four Spanish centers. Personal information, family history, and tumor information were registered.
Germinal genetic analysis was performed in patients who met current criteria of a hereditary syn-
drome at the time of diagnosis. The median age at diagnosis was 44 years. The majority (73.3%) of
tumors were diffuse, and 78.3% were diagnosed in an advanced stage. Familial aggregation of GC
was present in 18/117 (15.4%) cases, and 5/117 (4.3%) met criteria for familial GC. MMR-IHC was
performed in 126/309 (40.7%) tumors: 4/126 (3.1%) had loss of expression in MLH1/PMS2, without
an associated germline mutation. Sixteen germline genetic analyses were performed, detecting a
pathogenic variant in four (25%) cases: one in BRCA2, one in TP53, and two in CDH1. Most EOGC
are diffuse and diagnosed in an advanced stage. In these patients, DNA MMR system deficiency is
uncommon. Although familial aggregation was observed in only 15% of cases, a germline mutation
was found in 25% of patients tested with clinical criteria. This demonstrates that EOGC has a marked
genetic heterogeneity, reinforcing the importance of an accurate genetic counseling and enhancing
the emerging use of multigene panels.
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1. Introduction
Gastric cancer (GC) is the fifth most common and the third most deadly cancer in
the world [1], representing a worldwide health problem [2]. The average age at diagnosis
is 60 years, only 7% occur before age 50 and 2% before age 40 [3]. The etiology of GC is
multifactorial, with Helicobacter pylori, diet factors, and tobacco being the main environ-
mental agents implicated in its pathogenesis [4]. Although most GC cases are sporadic, a
familial aggregation is observed in approximately 10% of cases, with an underlying genetic
cause identified in up to 5% of all GC [5]. Familial characteristics that suggest a hereditary
predisposition include the existence of several affected family members, an autosomal
dominant pattern of inheritance, disease presentation at young ages, and association with
other extra-gastric neoplasms [6].
In terms of these assumptions, there are mainly three clinical situations where familial
predisposition to GC may be found [7]. First, hereditary syndromes with higher risk
for GC, including two entities: gastric adenocarcinoma and proximal polyposis of the
stomach (GAPPS) [8], and the most common inherited GC syndrome, hereditary diffuse
gastric cancer (HDGC). It is characterized by two or more cases of GC at any age in first
or second relatives, with at least one confirmed diffuse gastric cancer (DGC); or personal
history of DGC before the age of 50; or personal or family history (first- or second-degree
relatives) of DGC and lobular breast cancer, with one being diagnosed before 70 years [9].
This syndrome is mainly caused by CDH1 germline mutations, which encode the tumor
suppressor protein E-cadherin. However, during the last years, another gene, CTNNA1,
has also been identified in HDGC families [10].
Other clinical situations are hereditary syndromes with higher risk for GC and other
tumors, including Lynch syndrome and, less commonly, familial adenomatous polyposis
(FAP), Peutz–Jeghers syndrome, juvenile polyposis, Li–Fraumeni syndrome, and Cowden
syndrome [11], with germline mutations in different genes. The last clinical situation is
familial intestinal gastric cancer (FIGC) characterized by familial aggregation of intestinal
GCs without an identified inherited cause. FIGC is defined as two or more cases of GC in
first-degree (FDR) or second-degree relatives (SDR), with at least one confirmed case of
intestinal histology in someone younger than 50 years, or three or more confirmed cases of
intestinal GC in FDR or SDR, regardless of age [12,13].
In spite of this, the genetic cause is not identified in a high percentage of GC pa-
tients [14,15]. This fact is especially important in early-onset gastric cancer cases (EOGC)
because 90% of these young patients do not have a family history, hampering identification
and early diagnosis [16]. The remaining 10% of EOGC cases that have a family history are
explained by the previously mentioned hereditary syndromes.
The definition of early onset gastric cancer (EOGC) varies across studies, but one
of the most accepted definitions includes those diagnosed at the age of 50 or younger.
Although the incidence of GC is declining globally, EOGC is increasing [17]. In fact, a
recent study has reported that nowadays EOGC comprises up to 30% of all cases of GC
in the United States [18]. EOGC has been associated with some clinical and pathological
characteristics, such as predomination of diffuse histology and infrequent association with
intestinal metaplasia [19,20]. Moreover, EOGC is usually diagnosed in an advanced stage,
associated with a high mortality. However, clinical and molecular features of EOGC have
been poorly described [16].
Identification of individuals at high risk of GC allows us to establish preventive
measures, early diagnosis, and personalized treatments; thus, we aimed to describe the
clinical, molecular, and genetic characteristics of EOGC (≤50 years) in order to identify
high-risk forms of GC.
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2. Materials and Methods
2.1. Study Population
Patients with GC diagnosed before 51 years old were retrospectively studied at four
centers in Spain between 1999 and 2018. The study was approved by the Institutional
Review Board (or Ethics Committee) of Hospital Clínic in Barcelona (register number
2015/0153, date of approval 22/04/2015).
Clinical and demographic data were evaluated through electronic clinical reports,
including environmental risks factors such as tobacco consumption, alcohol intake, and
Helicobacter pylori infection.
Personal and family history of GC and other tumors related with hereditary syndromes
(i.e., HDGC, Peutz–Jeghers syndrome, Lynch syndrome, familial adenomatous polyposis,
HBOC, juvenile polyposis, and Li–Fraumeni syndrome) were registered (including FDRs
and SDRs). Patients who met criteria of familial GC were also identified.
2.2. Tumor Characteristics
The tumor characteristics were analyzed by histological report. The location, di-
agnostic stage (TNM), histologic features (intestinal, diffuse, or mixed), and grade of
differentiation were considered.
Tumor mismatch repair (MMR) deficiency was evaluated by immunostaining in-
cluding analysis of MLH1, MSH2, MSH6, and PMS2 protein expression, as previously
described [21].
2.3. Germline Genetic Analysis
Germline genetic testing was performed on genomic DNA isolated from peripheral
blood leukocytes by both multiple ligation probe amplification analysis and direct sequenc-
ing. The analysis was performed through a commercial multigene panel (Trusight Cancer
v1, Illumina Inc., San Diego, CA, USA) involving the most frequent genes related to GC
germline predisposition (MLH1, MSH2, MSH6, PMS2, CDH1, EPCAM, BRCA1, BRCA2,
PALB2, TP53, APC, MUTYH, STK11, SMAD4/BMPR1A, PTEN).
The genetic test was performed in patients with available germline DNA who fulfilled
the diagnostic criteria of a hereditary syndrome related to GC at the time of diagnosis or
in whom the tumoral analysis of DNA mismatch repair proteins was altered (i.e., loss of
protein expression of MLH1, MSH2, MSH6, or PMS2) [13].
2.4. Statistical Analysis
All data were analyzed using the 22.0 SPSS software package (IBM SPSS Statistics for
Window, Version 22.0. Armonk, NY: IBM Corp.).
Baseline characteristics were described in percentages for categorical data, using
median, range, and interquartile range (IQR). When information was missing, the denomi-
nator was accordingly to patients with available data. Univariate binary logistic regression
was performed for selection of variables associated with the diagnosis of a hereditary can-
cer. For multivariable logistic regression analyses, only candidate variables with p-values
of ≤0.05 on univariate analysis were used in the final multivariate model. Odds ratios




Three hundred and nine patients with EOGC were included. Clinico-pathological
features of patients included in the study are summarized in Table 1.
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Table 1. Clinical characteristics of the patients (N = 309).
EOGC
Age (years) at diagnosis; median (IQR) 44 (40–48)
Gender, number (%):
Man 191 (61.8)
Environmental risk factors; number (%)
Helicobacter pylori infection 24/82 (29.3)
Smokers 77/169 (45.6)
Moderate or high alcohol consumers 21/105 (20)
Personal history of extra-gastric cancer (n = 309); number (%)
Breast and/or ovarian 5 (1.6)
Lung 1 (0.3)
Thyroid 1 (0.3)
Hodgkin lymphoma 1 (0.3)
Cervix 1 (0.3)
Familial history of cancer (n = 117); number (%)
GC 18 (15.4)
Colorectal 8 (6.8)
Ovarian and/or breast 15 (12.8)
Others 39 (33.3)
Criteria of familial GC 5 (4.3)
IQR, interquartile range; EOGC, early onset gastric cancer; GC, gastric cancer.
The median age at diagnosis was 44 years old (IQR 40-48, range 33), with a predomi-
nance of men, with 191 (61.8%) cases. Related to environmental risk factors, 77/169 (45%)
were smokers and 21/105 (20%) had chronic alcohol consumption, whereas in 24/82 (29%)
cases, a Helicobacter pylori infection was detected. Most of the patients were from Spain;
however, 8/309 (2.6%) were from South America, 4/309 (1.3%) were from Asia, and 4/309
(1.3%) were South African.
Out of the 309 (2.9%) patients, 9 had previously developed other tumors, including
breast and/or ovarian in 5/309 (1.6%), lung in 1/309 (0.3%), cervix in 1/309 (0.3%), thyroid
in 1/309 (0.3%), and Hodgkin lymphoma in 1/309 (0.3%).
A total of 18/117 (15.4%) patients presented familial aggregation of GC (≥1 FDR or
SDR affected), and 5/117 (4.3%) met criteria for FIGC. A total of 67/117 (57.2%) patients
had family history of cancers related with a hereditary syndrome, mainly ovarian and/or
breast in 15/117 (12.8%), followed by colorectal cancer in 8/117 (6.8%) cases and other
types of tumors in 39/117 (34%). Detailed characteristics are described in Table 1.
3.2. Tumor Characteristics
The predominant tumor histology was diffuse, observed in 118/161 (73.3%) of the
cases, and the signet ring cell subtype was detected in 38/118 (32%). Among patients
with diffuse GC and H. pylori information available, in 8/45 (17.8%), the infection was
present. Among patients with intestinal GC subtype with H. pylori status available, 3/14
(21.4%) were infected. No statistically significant differences regarding H. pylori infection
and histology subtype were found (p = 0.09). According to the WHO classification (2019),
the degree of differentiation only applies to the intestinal GC, and thus within this subtype,
9/43 (39.1%) were poorly differentiated tumors. Regarding tumor location, the most
common sites were the body in 111/203 (55%) and antrum in 50/203 (25%). An advanced
stage (III/IV) at diagnosis was present in 166/212 (78.3%) cases, and only in 44/212 (20.8%)
was the diagnosis at an early stage (I/II).
In 122/205 (59.5%) cases, surgery with or without chemotherapy was performed;
67/205 (32.7%) patients were treated with chemotherapy (CT) +/− radiotherapy (RT)
alone, and 16/205 (7.8%) patients did not receive a specific oncological treatment.
The immunohistochemistry of DNA mismatch repair proteins (MMR-IHC) was per-
formed in 126 out of 309 (40.7%) tumors, and only 4/126 (3.1%) showed loss of protein
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expression, specifically MLH1/PMS2 (Figure 1). The tumor and MMR-IHC characteristics
are shown in Table 2 and Figure 2, respectively.
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Figure 1. Immunohistochemistry of DNA mismatch repair proteins (MMR-IHC) in gastric cancer 
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Table 2. Characteristics of the tumors (N = 309). 
 EOGC 
Gastric location (N = 203); number (%) 
Cardias 3 (1.5) 
Fundus 18 (8.9) 
Body 111 (54.7) 
Antrum 50 (24.6) 
Extensive 21 (10.3) 
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Figure 1. Immunohistochemistry of DNA mismatch repair proteins (MMR-IHC) in gastric cancer
tissue loss of protein expression of MLH1 and PMS2, and normal protein expression of MSH2
and MSH6.
Table 2. Characteristics of the tumors (N = 309).
EOGC






Stage (N = 212); number (%)
I/II 44 (20.8)
III/IV 166 (78.3)
Histology (N = 161); number (%)
(a) Diffuse
Signet ring cell subset
118 (73.3)
38/118 (32.2)
(b) Intestinal 30 (18.6)
(c) Mixed 13 (8.1)
Tumor differentiation grade (N = 23/43) number (%) *
High grade (poorly differentiated) 9 (39.1)
Low-grade (well/moderately differentiated) 14 (60.9)
Treatment (N = 205) number (%)
Surgery 40 (19.5)
Surgery + chemotherapy 58 (31.2)
Chemotherapy 64 (28.3)
Surgery + chemotherapy + radiotherapy 24 (11.7)
Chemotherapy + radiotherapy 3 (1.5)
Palliative 16 (7.8)
EOGC, early onset gastric cancer. * According to the WHO classification (2019), the degree of differentiation only
applies to the intestinal type.
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Figure 3. Overall survival rate based on diagnostic stage (stage I–II vs. stage III–IV). There is a
significant difference in the 5-year survival rate: stage I-II 87% vs. stage III-IV 11.3%, p = 0.0001.
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3.3. Germline Genetic Analysis
Genetic analysis was performed in the 16 patients with available germline DNA out
of the 44 patients that fulfilled clinical criteria of germline testing. Among them, in 11/16
(68.7%) patients, the analysis was performed due to the fulfillment of criteria for HDGC, in
2/16 patients because they met criteria of HBOC; and in 3/16 cases, the genetic analysis
was performed on the basis of a somatic loss of expression of MLH1/PMS2 proteins at IHC.
In the remaining 28/44 patients, the analysis was not performed because the DNA was not
available.
A germline genetic mutation was identified in 4/16 (25%) cases, one at 49 years
old (with personal history of GC and breast cancer) and another three with GC younger
than 41 years old. The mutated genes detected were BRCA2 and TP53, and in two cases,
CDH1 (Table 3). Integrative Genomics Viewer was used for visualization of these variants;
Figure S1 shows an example of two of these variants. None of those patients had tumors
with loss of expression in DNA mismatch repair protein (MMR), and only one of them
reported family history of GC. Within four patients with an altered MMR-IHC, the germline
genetic analysis performed in three patients did not identify any pathogenic variant, and
in the remaining patient, the germline analysis could not be performed because he died
before the MMR-IHC was done.
Table 3. Characteristics in patients with hereditary syndromes.




















































hist., histology; GC, gastric cancer; MMR-IHC, immunohistochemistry of DNA mismatch repair proteins; MMR, tumor mismatch repair;
*, stop codon
3.4. Factors Associated with High Risk of Gastric Cancer
Personal characteristics as well as family history were analyzed in order to identify
risk factors of a hereditary GC syndrome (germline mutation identified). No statistically
significant factor associated with the presence of a germline mutation was identified.
However, family history of other neoplasms showed a trend towards statistical significance
with p = 0.057.
4. Discussion
It is well known that EOGC has clinical and pathological differences with older onset
GC [22], although their clinical and molecular characteristics have been poorly reported [16].
In the present study, we describe clinical, molecular, and genetic characteristics of 309 EOGC
patients. Our study shows that most of EOGC are histologically diffuse (73%, in comparison
with 32% in older patients), poorly differentiated, and diagnosed at an advanced stage,
supporting what has been previously described in other studies [18–20,23]. Moreover, as
the already reported trend of increasing rate in general population [24] of proximal GC
over the distal location, we observed in our study that more than half of the tumors were
located in the gastric body. This could be explained not only due to the diffuse histology,
Cancers 2021, 13, 3132 8 of 11
but also because the low incidence of Helicobacter pylori infection (less than 30%) and a high
proportion (almost 60%) of patients with positive oncological family history, suggesting a
different carcinogenesis process.
Although there are known characteristics of EOGC, there are some inconsistent data
between studies, i.e., some studies reported a female predominance [23], while in oth-
ers there was an increasing trend for males or without a significant difference between
genders [25,26]. In the present study, a male predominance was identified.
On the basis of different features, our study attempted to deepen in the clinical
and molecular characterization of EOGC with the ultimate goal of being able to identify
high-risk individuals and establish preventive measures, early diagnosis, and personal-
ized treatments.
Lynch syndrome (LS), one of the most common cancer hereditary syndromes, carries
a cumulative risk of GC of 11–19% [27,28]. However, DNA mismatch repair deficiency
is exceptional in GC [29]. In order to consider the diagnoses of possible LS, we analyzed
the MMR system deficiency, observing that loss of protein expression was an infrequent
event, and only 4/126 (3.1%) patients displayed it. The low incidence of MMR deficiency
in EOGC is probably related to the high proportion of diffuse tumors, wherein MSI is
less common [30] and also related to the fact that genomically stable tumors are usually
diagnosed at an earlier age [31]. Moreover, in cases with MMR deficiency, we did not
find a correlation with a germline mutation, suggesting a somatic loss origin due to
hypermethylation of the MLH1 promoter gene [32]. Thus, based upon our results, in
this subgroup of patients, systematically analysis of MMR deficiency to rule out Lynch
syndrome through IHC is likely not very useful.
Germline analysis was performed in 16 patients, representing 36% of patients who met
clinical criteria for genetic testing according with the current guideline at that moment of
the study (i.e., 2018–2019) [13]. Despite the fact that genetic testing could not be performed
in the whole cohort of patients (due to loss of follow up or death), we found a germline
mutation in 25% of tested patients. These mutations were located on BRCA2, CDH1, and
TP53 genes. Both patients with CDH1 germline mutations displayed familial history of
GC, while patients with BRCA2 and TP53 germline mutations showed familial history of
ovarian and breast cancer, and breast and colorectal cancer, respectively. Thus, although
familial aggregation of GC was present in only 15% of cases and the majority of patients
with a germline mutation did not have familial aggregation of GC, family history of other
tumors related with a hereditary syndrome was common. Therefore, this observation
reinforces that, although family history of GC is poorly predictive, a very accurate medical
personal and family history including any tumor type is mandatory in order to select the
appropriate candidates for genetic testing.
Analyzing other studies, Tedaldi et al. focused on 96 patients that fulfilled different
criteria such as HDGC criteria, suspected Lynch syndrome, familial aggregation, or pa-
tients with polyps and family history of GC. They sequenced 94 genes involved in cancer
predisposition, identifying eight different CDH1 pathogenic/likely patogenic mutations
in nine different patients with DGC and a mean age of almost 40 years. Although they
identified more variants in other genes, their carriers were patients with more than 50 years
old, and therefore they cannot be considered as an early onset cohort [33]. Moreover, a
Canadian cohort was studied using single-site and multi-gene panels. The authors identi-
fied mutations in CDH1 and BRCA2 in five and two patients with DGC before the age of 50,
respectively. Comparing with the present study, similar results were obtained, although the
TP53 gene was not identified in this cohort [34]. However, a study performed by Vogelaar
et al. did not identify any mutation neither in CDH1 nor in CTNNA1 in a cohort of 54 GC
EOGC patients [35].
The relevance of the diagnosis of a hereditary syndrome is the opportunity to establish
prevention and early diagnosis measures. For example, specifically in the context of CDH1
mutation carriers, most asymptomatic individuals do not have macroscopic lesions on
endoscopic examinations; however, intramucosal foci of gastric cancer, usually multiple,
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are observed in the surgical specimens. Therefore, it is recommended that one perform
prophylactic total gastrectomy in carriers of a pathogenic variant who are older than
20 years [36,37]. Annual endoscopic screening is reserved for individuals who do not
accept prophylactic gastrectomy, patients with a variant of uncertain significance, and
patients in whom the germline mutation has not been identified. This point is reflected in
our cohort, wherein the two patients with a CDH1 mutation were diagnosed at stage IV
(metastatic). In one case, two relatives were carriers of the mutation, with normal upper
gastroscopy but with multiple focuses of diffuse adenocarcinoma, both in early stages
(T1a and T1b, N0, M0). In the second patient, no additional CDH1 mutation carriers were
identified.
This study has some limitations, most of them because the data obtained were collected
retrospectively, which implies potential inclusion biases and the difficulty to obtain the
information of some variables: Epstein–Barr virus infection; associated gastritis; HER-2 or
PDL1 status; and, as mentioned previously, germline testing, which was only evaluated
in 16/44 (36%) of patients who met clinical criteria for genetic testing, and CTNNA1 was
not performed. Moreover, it is important to mention that H. pylori status was available
in only 82 cases, being positive in 24 of them (29%); however, no difference regarding H.
pylori prevalence among diffuse and intestinal histology was detected. In this context,
other studies have been focused on the role of H. pylori infection and EOGC development,
suggesting that it is important for tumor development [24], but to a lesser extent than in
older GC patients [38]. Moreover, Rugge, et al. confirmed that H. pylori infection was
significantly associated with both diffuse and intestinal histotypes [39]. In this sense, the
low prevalence of H. pylori in our cohort, and the lack of differences in H. pylori status
between histotypes, suggest that the implication of this infection in the carcinogenesis
process is less relevant in EOGC, although prospective and large cohorts are needed to
deepen in this observation.
The main strength of our study is that it describes not only clinical but also histological
and molecular data of a large cohort of more than 300 patients with EOGC, although we
are aware of the limitations associated to an observational and retrospective study.
5. Conclusions
Our results show that that most early onset GC cases are diagnosed in advanced
stage, have diffuse histology, and have infrequent DNA mismatch repair somatic deficiency.
Moreover, early onset GC has a marked genetic heterogeneity. Thus, it is essential to
consider familial history of tumors, not only GC, but also and more importantly other
tumors related with hereditary syndromes (such as colorectal, breast, and ovarian cancer),
in order to select adequate patients to perform a suitable genetic counseling and enhance
the emerging use of multigene panels.
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